2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2014 Featured Talks » Omics as a Disruptive Technology: Implications for Cancer Therapy

Razelle Kurzrock, part 1 from MCC Industry Relations on Vimeo.

Razelle Kurzrock, part 2 from MCC Industry Relations on Vimeo.

Razelle Kurzrock, MD
Murray Professor of Medicine, Sr. Deputy Center Director, Clinical Science
Director, Center for Personalized Therapy & Clinical Trials Office
Vice Chief Division of Hematology & Oncology, Moores Cancer Center

Dr. Razelle Kurzrock joined UC San Diego Moores Cancer Center in November 2012 as Senior Deputy Center Director for Clinical Science, overseeing the clinical trials program, and heading the newly established Center for Personalized Therapy. Dr. Kurzrock is also Vice Chief of the Division of Hematology-Oncology Division in the UC San Diego School of Medicine. Previously, Dr. Kurzrock spent many years at University of Texas M.D. Anderson Cancer Center, where she began her career as an oncologist in 1984. While there she created one of the largest hypothesis-driven Phase I clinical trials program in the world, leading to the formation in 2007 of the clinical trials department, with her as its founding chair. In FY2012, the program enrolled about 1,200 patients on 128 therapeutic trials. Dr. Kurzrock's approach emphasizes using molecular profiling to match patients with targeted therapies.

Dr. Kurzrock has served as the PI on more than 90 clinical trials, mainly using novel targeted molecules, several of which have gone on to FDA approval. She has also created and directed two innovative education programs: the MS/Ph.D. program in Patient-Based Biological Research at the University of Texas Graduate School of Biomedical Sciences and the Phase I Clinical Trials Fellowship. She has published nearly 450 peer-reviewed articles in a variety of elite medical journals. In addition, she is Chair of the Southwest Oncology Group (SWOG) Early Therapeutics Committee and on their Board of Governors.